The addition of atezolizumab (Tecentriq) to a modified regimen of FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in patients with previously untreated, highly mutated, metastatic colorectal cancer. The ATEZOTRIBE phase II study from Italy showed a median overall survival of 33.0 months in the atezolizumab group versus 27.2 months in the control group after 4 years of follow-up (median 45.2 months) (HR = 0.78, 80% CI = 0.61–0.98).[2] The FOLFOXIRI/bevacizumab plus atezolizumab regimen improved overall survival in patients with metastatic colorectal cancer.[2] The greatest benefit was in patients with high tumor mutational burden (TMB-high, HR = 0.03, 95% CI = 0.00–0.34) and high Immunoscore-IC (HR = 0.42, 95% CI = 0.18–0.99), with interaction P = 0.043 for TMB and P = 0.092 for Immunoscore.[2] In patients with pMMR status (202 patients), median survival was 30.8 months versus 29.2 months (HR = 0.80, 80% CI = 0.63–1.02, P = 0.117).[2] The researchers identified subgroups with pMMR, TMB-high and/or Immunoscore IC-high as suitable for further development of this treatment.[2]